GW Pharmaceuticals plc gibt Finanzergebnisse und operative Fortschritte für das am 30. Juni 2019 abgeschlossene zweite Quartal bekannt

06.08.2019   GW Pharmaceuticals plc Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2019     – Epidiolex U.S. Q2 net sales of $68.4 million – – Positive CHMP opinion clears way for an expected European approval in October – – Conference call today at 4:30 p.m. EST – CARLSBAD,